The present invention relates to a pharmaceutical composition comprising a compound of formula (I) wherein R1 is selected from halogen, substituted or unsubstituted C1 to C6 alkyl, substituted or unsubstituted C1 to C6 alkenyl, substituted or unsubstituted C1 to C6 alkinyl, substituted or unsubstituted C1 to C6 acyl, C1 to C6 haloalkyl, H, NO2, OH, SH, NH2, C1 to C6 alkoxy, CN and N(CH3)2, substituents being selected from OH, SH and NH2, the term "substituted" providing for 1 or 2 substituents； R2 is selected from H, substituted or unsubstituted C1 to C6 alkyl, substituted or unsubstituted C1 to C6 alkenyl and substituted or unsubstituted C1 to C6 alkinyl, substituents being selected from OH, SH and NH2, the term "substituted" providing for 1 or 2 substituents； A, B, C and D are independently selected from N and CH； Z is selected from NH, S, CH2, a direct single bond, and a direct double bond； V is selected from substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, heteroatoms in said heterocycloalkyl and said heteroaryl being selected from N, O and S, the total number of heteroatoms in said heterocycloalkyl and said heteroaryl being 1, 2, 3 or 4, the term "substituted" providing for 1, 2 or 3 substituents, substituents being selected from d to C6 alkyl, C1 to C6 alkenyl, C1 to C6 alkinyl, C1 to C6 acyl, C1 to C6 haloalkyl, NO2, OH, SH, NH2, C1 to C6 alkoxy, CN and N(CH3)2； and m is 0 or an integer selected from 1, 2, 3, 4 and 5.La présente invention concerne une composition pharmaceutique comprenant un composé de formule (I) dans laquelle : R1 est sélectionné parmi un halogène, un alkyle en C1 à C6 substitué ou non substitué, un alcényle en C1 à C6 substitué ou non substitué, un alcynyle en C1 à C6 substitué ou non substitué, un acyle en C1 à C6 substitué ou non substitué, un haloalkyle en C1 à C6, H, NO2, OH, SH, NH2, un alkoxy en C1 à C6, CN et N(CH3)2, l
